Cancel
About Don Healey
Don Healey, the Chief Technology Officer at Adicet since October 2020, has an extensive background in biopharmaceuticals, specializing in cellular therapies and immunology.
Known information
Don Healey joined Adicet as the Chief Technology Officer in October 2020, bringing a wealth of experience from the biopharmaceutical industry, particularly in cellular therapies and immunology. Before joining Adicet, he worked at KBI Biopharma Inc., where he played a crucial role in establishing process development, manufacturing, quality control, and facilities management for biopharmaceutical clients. Healey also served as the Chief Scientific Officer at Opexa Therapeutics, Inc., where he oversaw all pre-clinical scientific development, closed-system process design, and the scaling of Opexa’s autologous T-cell immunotherapy. His earlier roles include Director of Immunology at Argos Therapeutics Inc. and Group Leader for Immunology at ML Laboratories in the UK. Healey earned his Ph.D. from the University of London and holds a B.Sc. in Cellular Pathology from Bristol University.
About Adicet Bio
Adicet Bio is a biotechnology company specializing in the development of allogeneic, genetically modified gamma delta T cells for treating autoimmune diseases and cancer, with offices in Redwood City, CA, and Boston, MA.
Report inaccurate information
